Liraglutide at a glance
| Detail | What the sources say |
|---|---|
| Brands (Novo Nordisk) | Victoza® (type 2 diabetes); Saxenda® (weight management) |
| Generics | First US generic approved in 2024 |
| Form and rhythm | Multi-dose pen, injected under the skin once a day |
| Where approved | US (FDA, 2010 and 2014) and EU (EMA, 2009 and 2015) |
From the label to the app
| What the label says | What PepLabo does with it |
|---|---|
| Missed dose: continue with the next scheduled dose; no extra dose [1][2]. | A follow-up arrives 30 minutes after a missed dose time. PepLabo never suggests an extra dose. |
| More than 3 days since the last dose: both labels describe restarting at the starting dosage [1][2]. | Today shows your last dose and how long ago it was, so a gap of several days is visible at a glance. PepLabo never changes a dose. |
| Rotate within the same region to reduce the risk of cutaneous amyloidosis [1][2]. | Each log asks for the site on a front and back body map, and a weekly heat map shows which areas you used. |
What PepLabo does and does not do
| PepLabo does | PepLabo does not |
|---|---|
| Record each dose with the date, time and amount you enter, and the site for injections | Suggest a dose, a schedule change or a medicine |
| Remind you 15 minutes before, at the dose time, and 30 minutes after a missed dose | Tell you what to do after a missed dose; the leaflet and your prescriber do |
| Put check-ins, weight and doses on one timeline | Interpret symptoms or judge progress |
| Keep your records on your phone, with no account needed to track | Use analytics, advertising or tracking SDKs, or write to Apple Health |
| Create a PDF of your dose log for your clinician (Pro) | Replace your clinician or pharmacist |
